nivolumab moa | Nivolumab - StatPearls

Keyword	CPC	PCC	Volume	Score	Length of keyword
nivolumab moa	0.55	0.8	2971	8	13
nivolumab	1.65	0.3	9781	36	9
moa	0.57	0.3	8762	98	3

Keyword	CPC	PCC	Volume	Score
nivolumab moa	0.37	0.7	6929	6
nivolumab macmillan	1.23	0.2	8271	61
nivolumab manufacturer	1.98	0.8	5073	83
nivolumab monotherapy	1.98	0.5	1005	62
nivolumab mode of action	1.07	0.9	1980	21
nivolumab monograph	1.46	1	966	17
nivolumab monoclonal antibody	0.03	0.4	872	56
nivolumab molecular weight	1.15	0.5	872	98
nivolumab mouse cross reactivity	1.76	0.8	6392	86
nivolumab maintenance therapy	0.63	0.8	9681	27
nivolumab manufacturing process	0.54	0.8	1730	80
nivolumab mouse pd-1	1.86	0.3	3573	10

Search Results related to nivolumab moa on Search Engine

Nivolumab - StatPearls - NCBI Bookshelf
nih.gov

https://www.ncbi.nlm.nih.gov/books/NBK567801/

WEBDec 5, 2022 · USA.gov. Nivolumab is a medication used to manage and treat metastatic melanoma and several other tumors. It is a monoclonal antibody that targets the anti-PD1 receptor, an immune checkpoint. This activity outlines the indications, mechanism of action, and administration for nivolumab to manage advanced cancers.

DA: 27 PA: 98 MOZ Rank: 34

Nivolumab - Wikipedia
wikipedia.org

https://en.wikipedia.org/wiki/Nivolumab

WEBNivolumab is used as a first-line treatment for inoperable or metastatic melanoma in combination with ipilimumab if the cancer does not have a mutation in BRAF, and as a second-line treatment for inoperable or metastatic melanoma following treatment of ipilimumab and, if the cancer has a BRAF mutation, a BRAF inhibitor.

DA: 75 PA: 45 MOZ Rank: 24

Nivolumab: Uses, Interactions, Mechanism of Action | DrugBank …
drugbank.com

https://go.drugbank.com/drugs/DB09035

WEBNivolumab is indicated to treat unresectable or metastatic melanoma, melanoma as adjuvant treatment, resectable or metastatic non-small cell lung cancer, small cell lung cancer, advanced renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, microsatellite instability-high or ...

DA: 28 PA: 10 MOZ Rank: 5

Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332892/

WEBFeb 10, 2017 · Nivolumab, a fully human immunoglobulin G4 PD-1 immune checkpoint inhibitor antibody, blocks PD-1 and promotes antitumor immunity, and it is effective for treating non-small-cell lung cancer (NSCLC), melanoma, renal cell …

DA: 91 PA: 93 MOZ Rank: 85

Mechanism of Disease & Mechanism of Action | OPDIVO® (nivolumab)
opdivohcp.com

https://www.opdivohcp.com/moa

WEBOPDIVO ® (nivolumab), as a single agent, is indicated for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC.

DA: 42 PA: 24 MOZ Rank: 72

Opdivo | European Medicines Agency
europa.eu

https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo

WEBnivolumab. Medicine Human. Overview. Opdivo is a cancer medicine used in adults to treat the following: melanoma, a type of skin cancer; a lung cancer called non-small cell lung cancer (NSCLC); advanced renal cell carcinoma, a kidney cancer; classical Hodgkin lymphoma, a cancer of the lymphocytes (a type of white blood cell);

DA: 94 PA: 76 MOZ Rank: 53

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell …
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa1613493

WEBJun 22, 2017 · Nivolumab has been associated with longer overall survival than docetaxel among patients with previously treated non–small-cell lung cancer (NSCLC). In an open-label phase 3 trial, we compared...

DA: 91 PA: 3 MOZ Rank: 86

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in …
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa1200690

WEBPublished June 28, 2012. N Engl J Med 2012;366: 2443 - 2454. DOI: 10.1056/NEJMoa1200690. VOL. 366 NO. 26. Abstract. Background. Blockade of programmed death 1 (PD-1), an inhibitory receptor...

DA: 32 PA: 50 MOZ Rank: 88

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung …
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa1910231

WEBSep 28, 2019 · Combination therapy with nivolumab plus ipilimumab has resulted in longer overall survival than previous standard therapies in patients with melanoma 8 and in those with renal-cell carcinoma. 9...

DA: 67 PA: 51 MOZ Rank: 65

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in ... - PubMed
nih.gov

https://pubmed.ncbi.nlm.nih.gov/31629915/

WEBIntroduction: Nivolumab monotherapy is approved in the United States for third-line or later metastatic small cell lung cancer based on pooled data from nonrandomized and randomized cohorts of the multicenter, open-label, phase 1/2 trial of nivolumab ± ipilimumab (CheckMate 032; NCT01928394 ).

DA: 58 PA: 8 MOZ Rank: 90